Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.68 |
| ▸ | KDR | P35968 | 11/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837016 | 0.87 | EGFR (0.73) | EGFRKDRPDGFRBPDGFRALCK | |
| SCHEMBL17837013 | 0.77 | EGFR (0.70) | EGFRKDRPDGFRBPDGFRA | |
| SCHEMBL2256420 | 0.76 | POLB (0.67) | GAKPOLBRAD52TSHR | |
| SCHEMBL17837012 | 0.75 | PDGFRB (1.00) | EGFRKDRPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL13276260 | 0.73 | EGFR (0.71) | EGFRKDRPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL17837021 | 0.73 | KDR (0.75) | EGFRKDRPDGFRBPDGFRAPOLB | |
| SCHEMBL17860686 | 0.73 | KDR (0.62) | EGFRKDRPDGFRBPDGFRAGAA | |
| SCHEMBL17837027 | 0.71 | KDR (0.72) | EGFRKDRPDGFRBPDGFRAGAA | |
| SCHEMBL17837007 | 0.70 | KDR (0.63) | EGFRKDRPDGFRBPDGFRATSHR | |
| SCHEMBL17837009 | 0.70 | EGFR (0.63) | EGFRKDRPDGFRBPDGFRATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-12-28 | — | — | US | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2016100495-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | ERBB2, MAP2, TUBB6 | EGFR 8/4885KDR 167/4885PDGFRB 232/4885 |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | ERBB2, DCK, DHFR | EGFR 38/4885KDR 402/4885PDGFRB 394/4885 |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | ERBB2, DCK, DHFR | EGFR 38/4885KDR 402/4885PDGFRB 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.